In this issue of *Blood*, Scoville et al report an original mechanism by which the aryl hydrocarbon receptor (AHR) allows acute myeloid leukemia (AML) to escape the natural killer (NK) cell-mediated antitumor immunosurveillance by increasing expression of microRNA (miR)–29b, thereby inhibiting NK-cell maturation and function.1

The seminal work by Ruggeri et al demonstrated that NK cells are critical effector cells in graft-versus-leukemia in AML after hematopoietic stem cell transplantation.2 AML patients at diagnosis show deeply impaired NK-cell function against leukemia, with decreased capacity to release cytokines, such as interferon γ, and reduced cytotoxicity with low expression of intracellular cytolytic enzymes (perforin, granzymes). In that context, NK-cell defects are often associated with a specific AML transcription program,3 emphasizing the intimate relationship taking place between both cell types during leukogenesis. Mechanisms by which AML induces such profound and sustained NK cell defects are still largely unknown.4 Consequently, there is a quest to develop strategies to reactivate antitumor NK-cell function in support of patients’ treatment at diagnosis or after complete remission.

Scoville et al identified AHR as a key factor in the NK cell/leukemia cross talk resulting in the inhibition of the NK-cell maturation and function, and in reducing resistance of AML blasts to NK-cell-mediated killing (see figure). Soluble ligands secreted by AML cells, which remain unidentified, trigger the AHR pathway in NK cells, which in turn increases the transcription of miR-29b and thereby inhibits NK-cell maturation, with a blockade at an immature and poorly functional differentiation stage. The importance of miR-29b in regulating NK-cell maturation and function in the context of AML, previously described in mouse models by the authors,5 was herein confirmed in humans. AHR appears to be a direct regulator of miR-29b transcription through its binding onto the miR-29a/b1 promoter, suggesting the AHR pathway is a major mechanism by which AML dampens antitumor immunity. Treatment with an AHR antagonist of NK cells cocultured with AML could abrogate increased miR-29b expression and restore NK-cell maturation and function. Interestingly, AHR was also involved in AML survival and its resistance to NK-cell cytotoxicity.

There is growing interest in the role of AHR in the emergence and progression of cancer. Notably, AHR has been associated with the regulation of numerous biological processes important in tumorogenesis, including proliferation, migration, and inflammatory signaling.6 In addition, AHR expression is increased in tumors relative to healthy surrounding tissues. However, AHR function varies according to the cell where it is expressed. Together with the wide diversity of endogenous and exogenous AHR ligands, it explains the difficulty in addressing the role of this transcription factor in cancer. Scoville et al showed that the AHR pathway could not only promote intrinsic capacities of resistance and survival of tumor cells, but also generate an inhibiting microenvironment preventing the antitumor immune response. Importantly, the AHR/miR-29b pathway did not directly inhibit NK-cell function when AHR was triggered in mature NK cells but impaired the upstream development of the NK-cell precursors. This observation is reminiscent of previous data by Roeven et al.

---

**Comment on Scoville et al, page 1792**

**AHR: leukemic countermeasure against NK cells**

**Nicolas Dulphy | Université Paris Diderot**

*In this issue of Blood*, Scoville et al report an original mechanism by which the aryl hydrocarbon receptor (AHR) allows acute myeloid leukemia (AML) to escape the natural killer (NK) cell–mediated antitumor immunosurveillance by increasing expression of microRNA (miR)–29b, thereby inhibiting NK-cell maturation and function.1

The seminal work by Ruggeri et al demonstrated that NK cells are critical effector cells in graft-versus-leukemia in AML after hematopoietic stem cell transplantation.2 AML patients at diagnosis show deeply impaired NK-cell function against leukemia, with decreased capacity to release cytokines, such as interferon γ, and reduced cytotoxicity with low expression of intracellular cytolytic enzymes (perforin, granzymes). In that context, NK-cell defects are often associated with a specific AML transcription program,3 emphasizing the intimate relationship taking place between both cell types during leukogenesis. Mechanisms by which AML induces such profound and sustained NK cell defects are still largely unknown.4 Consequently, there is a quest to develop strategies to reactivate antitumor NK-cell function in support of patients’ treatment at diagnosis or after complete remission.

Scoville et al identified AHR as a key factor in the NK cell/leukemia cross talk resulting in the inhibition of the NK-cell maturation and function, and in reducing resistance of AML blasts to NK-cell-mediated killing (see figure). Soluble ligands secreted by AML cells, which remain unidentified, trigger the AHR pathway in NK cells, which in turn increases the transcription of miR-29b and thereby inhibits NK-cell maturation, with a blockade at an immature and poorly functional differentiation stage. The importance of miR-29b in regulating NK-cell maturation and function in the context of AML, previously described in mouse models by the authors,5 was herein confirmed in humans. AHR appears to be a direct regulator of miR-29b transcription through its binding onto the miR-29a/b1 promoter, suggesting the AHR pathway is a major mechanism by which AML dampens antitumor immunity. Treatment with an AHR antagonist of NK cells cocultured with AML could abrogate increased miR-29b expression and restore NK-cell maturation and function. Interestingly, AHR was also involved in AML survival and its resistance to NK-cell cytotoxicity.

There is growing interest in the role of AHR in the emergence and progression of cancer. Notably, AHR has been associated with the regulation of numerous biological processes important in tumorogenesis, including proliferation, migration, and inflammatory signaling.6 In addition, AHR expression is increased in tumors relative to healthy surrounding tissues. However, AHR function varies according to the cell where it is expressed. Together with the wide diversity of endogenous and exogenous AHR ligands, it explains the difficulty in addressing the role of this transcription factor in cancer. Scoville et al showed that the AHR pathway could not only promote intrinsic capacities of resistance and survival of tumor cells, but also generate an inhibiting microenvironment preventing the antitumor immune response. Importantly, the AHR/miR-29b pathway did not directly inhibit NK-cell function when AHR was triggered in mature NK cells but impaired the upstream development of the NK-cell precursors. This observation is reminiscent of previous data by Roeven et al.
showing that stimulation by an AHR antagonist could potentiate the generation of cytotoxic NK cells from CD34+ hematopoietic stem and progenitor cells (HSPCs) in humans. AML evasion of cytotoxic NK cells from CD34+ hematopoietic stem and progenitor cells might be necessary to identify which ligand is be necessary to identify which ligand is the ligand involved and their maturation stages may respond differently to the trig- Phagocytes, Granulocytes, and Myelopoiesis Comment on Hind et al, page 1818

Maestro endothelium conducts the neutrophils

Ricardo Grieshaber-Bouyer and Peter A. Nigrovic | Harvard Medical School

In this issue of Blood, Hind and colleagues leverage a custom microscale system to demonstrate that endothelial cells communicate with neutrophils via interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the presence of live Pseudomonas aeruginosa to enhance neutrophil transmigration.¹

Neutrophils are a critical first line in the defense against infection but also contribute to pathologic inflammation. Their entry into tissues is therefore carefully regulated by a network of cells, cytokines, chemokines, and adhesion molecules.²

The work by Scoville et al constitutes a major step in the identification of drug targets to restore immunosurveillance against leukemia and eliminate residual leukemia posttreatment by restoring NK-cell function. However, prior to targeting the AHR pathway, further analyses will be necessary to identify which ligand is produced by AML cells to inhibit NK-cell maturation, how AML interferes with other immune cells through the AHR pathway, and how miR-29b is involved in these processes.

Conflict-of-interest disclosure: N.D. has been invited to scientific meetings organized by Bristol-Myers Squibb, Celgene, Celyad, and Innate Pharma.

REFERENCES


DOI 10.1182/blood-2018-09-873570
© 2018 by The American Society of Hematology